These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1114 related articles for article (PubMed ID: 16940812)
1. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases. El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812 [TBL] [Abstract][Full Text] [Related]
2. [The use of GnRH analogues in early and advanced breast carcinomas]. Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613 [TBL] [Abstract][Full Text] [Related]
3. Ovarian ablation as treatment for young women with breast cancer. Davidson NE J Natl Cancer Inst Monogr; 1994; (16):95-9. PubMed ID: 7528032 [TBL] [Abstract][Full Text] [Related]
4. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings. McDonald Wade S; Hackney MH; Khatcheressian J; Lyckholm LJ Oncology; 2008; 75(3-4):192-202. PubMed ID: 18841034 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. Carlson RW; Theriault R; Schurman CM; Rivera E; Chung CT; Phan SC; Arun B; Dice K; Chiv VY; Green M; Valero V J Clin Oncol; 2010 Sep; 28(25):3917-21. PubMed ID: 20679610 [TBL] [Abstract][Full Text] [Related]
6. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Prowell TM; Davidson NE Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635 [TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Tan SH; Wolff AC Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122 [TBL] [Abstract][Full Text] [Related]
8. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Buzdar AU; Vergote I; Sainsbury R Breast J; 2004; 10(3):211-7. PubMed ID: 15125747 [TBL] [Abstract][Full Text] [Related]
9. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Monnier AM Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927 [TBL] [Abstract][Full Text] [Related]
10. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
11. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen. Carpenter R Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588 [TBL] [Abstract][Full Text] [Related]
13. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long? Kaufmann M; Rody A Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229 [TBL] [Abstract][Full Text] [Related]
14. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950 [TBL] [Abstract][Full Text] [Related]
15. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. Adjuvant Breast Cancer Trials Collaborative Group J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996 [TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in metastatic breast cancer. Buzdar AU; Plourde PV; Hortobagyi GN Semin Oncol; 1996 Aug; 23(4 Suppl 9):28-32. PubMed ID: 8824462 [TBL] [Abstract][Full Text] [Related]
17. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. Dodwell D; Williamson D Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236 [TBL] [Abstract][Full Text] [Related]
18. Hormonal approaches to breast cancer treatment and prevention: an overview. Vogel CL Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459 [TBL] [Abstract][Full Text] [Related]
19. Hormonal therapy for advanced breast cancer. Rugo HS Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449 [TBL] [Abstract][Full Text] [Related]
20. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]